公开(公告)号：US10905772B2

公开(公告)日：2021-02-02

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Veniant-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K38/26 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20180280474A1

公开(公告)日：2018-10-04

申请号：US15765144

申请日：2016-09-30

Applicant: AMGEN INC.

Inventor： Jing Xu ,  Shanaka Stanislaus ,  Mei-Hsiu M. Chen ,  Clarence H. Hale ,  Murielle Veniant-Ellison

IPC: A61K38/18 ,  A61P1/00 ,  A61P1/16

Abstract: The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.

公开(公告)号：US20140213512A1

公开(公告)日：2014-07-31

申请号：US14241848

申请日：2012-08-30

Applicant: Amgen Inc.

Inventor： Murielle Marie Ellison ,  Shanaka Stanislaus ,  Jing Xu

IPC: A61K38/18

CPC classification number: A61K38/1825

Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease

Abstract translation: 提供了使用FGF21多肽治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是1型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰​​岛素水平升高，糖尿病性肾病，神经病变，视网膜病变，缺血性心脏病，外周血管疾病和脑血管疾病

公开(公告)号：US12214051B2

公开(公告)日：2025-02-04

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan Cheng ,  Chawita Netirojjanakul ,  Jerry Ryan Holder ,  Bin Wu ,  James R. Falsey ,  Bradley J. Herberich ,  Kelvin Sham ,  Leslie P. Miranda ,  Shu-Chen Lu ,  Murielle M. Venient-Ellison ,  Shanaka Stanislaus ,  Junming Yie ,  Jing Xu

IPC: A61K47/68 ,  A61K39/395 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20180000898A1

公开(公告)日：2018-01-04

申请号：US15671923

申请日：2017-08-08

Applicant: Amgen Inc.

Inventor： Murielle Marie Ellison ,  Shanaka Stanislaus ,  Jing Xu

IPC: A61K38/18

CPC classification number: A61K38/1825

Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease